kn026
mAbexperimentalMulti-specific
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Sep 17, 2018 (NCT03619681)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06998771 | Phase 2 | Jun 15, 2025 | Shanghai JMT-Bio Inc. |
| NCT06747338 | Phase 3 | Dec 16, 2024 | Shanghai JMT-Bio Inc. |
| NCT06023758 | Phase 2 | Sep 22, 2023 | Peking University |
| NCT05985707 | Phase 2 | Aug 15, 2023 | Peking University |
| NCT05838066 | Phase 3 | Jul 31, 2023 | Shanghai JMT-Bio Inc. |
| NCT05427383 | Phase 2/Phase 3 (Phase 3) | Apr 7, 2022 | Shanghai JMT-Bio Inc. |
| NCT04881929 | Phase 2 | Jun 15, 2021 | Alphamab Co., Ltd. |
| NCT04521179 | Phase 2 | Dec 7, 2020 | Alphamab Co., Ltd., Chinese Academy of Medical Sciences, Peking University |
| NCT04165993 | Phase 2 | Dec 1, 2019 | Alphamab Co., Ltd. |
| NCT04040699 | Phase 1 | Aug 8, 2019 | Alphamab Co., Ltd., Peking University |
| NCT03847168 | Phase 1 | Jun 18, 2019 | Alphamab Co., Ltd. |
| NCT03925974 | Phase 2 | Jun 17, 2019 | Alphamab Co., Ltd. |
| NCT03619681 | Phase 1 | Sep 17, 2018 | Alphamab Co., Ltd. |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alphamab Co., Ltd. | For profit | 7 | 6 | 2 | 2018 |
| Peking University | Academic/Hospital | 4 | 3 | 2 | 2019 |
| Shanghai JMT-Bio Inc. | For profit | 4 | 4 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1